Who makes Gentamicin in Uniject Pre-filled syringe?

Gentamicin in Uniject Pre-filled syringe is developed by Johns Hopkins Bloomberg School of Public Health.

What development phase is Gentamicin in Uniject Pre-filled syringe in?

Gentamicin in Uniject Pre-filled syringe is FDA-approved (marketed).

Last reviewed 2026-05-14 · How we verify

Gentamicin in Uniject Pre-filled syringe

Johns Hopkins Bloomberg School of Public Health · FDA-approved active Small molecule Quality 0/100

Gentamicin in Uniject Pre-filled syringe, marketed by the Johns Hopkins Bloomberg School of Public Health, holds a niche position in the antibiotic market. The key composition patent expiring in 2028 provides a period of exclusivity, enhancing its competitive advantage. The primary risk is the lack of revenue data, which may indicate limited commercial impact or market penetration.

At a glance

Generic name	Gentamicin in Uniject Pre-filled syringe
Sponsor	Johns Hopkins Bloomberg School of Public Health
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Determination of Gentamicin Dosing in Neonatal Patients (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Gentamicin in Uniject Pre-filled syringe CI brief — competitive landscape report
Gentamicin in Uniject Pre-filled syringe updates RSS · CI watch RSS
Johns Hopkins Bloomberg School of Public Health portfolio CI